MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Protalix BioTherapeutics Company Profile (NYSE:PLX)

Consensus Ratings for Protalix BioTherapeutics (NYSE:PLX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.63 (226.09% upside)

Analysts' Ratings History for Protalix BioTherapeutics (NYSE:PLX)
Show:
DateFirmActionRatingPrice TargetActions
4/4/2016Rodman & RenshawInitiated CoverageBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Jefferies GroupReiterated RatingBuy$2.30 -> $1.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2014R. F. LaffertyLower Price TargetBuy$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2014JPMorgan Chase & Co.Lower Price TargetOverweight$8.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/6/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha